2025年7月28日,和铂医药-B(02142)发布公告,预期截至2025年6月30日止6个月的溢利约6800万美元至7400万美元。股价当日上涨8.33%,报10.40港元。预期溢利增长主要得益于与阿斯利康等全球制药公司的战略合作,以及新取得的创新产品许可和合作带来的收入增加。
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.